Lexicon Q2 net loss $53.4M; INPEFA sales $1.6M; ZYNQUISTA NDA resubmitted

LEXICON PHARMACEUTICALS, INC.

2024-Q2 EPS reported -$0.37 revenue$2,777,000

Net loss $53.4M ($0.17/sh) vs $44.9M a year ago; cash & investments $310M, up from $170M.
INPEFA (sotagliflozin) net sales $1.6M; commercial launch ongoing.
NDA for ZYNQUISTA in type 1 diabetes resubmitted; PDUFA goal date Dec 20, 2024.
SONATA Phase 3 study of sotagliflozin in hypertrophic cardiomyopathy commenced.
PROGRESS Phase 2b (LX9211) for DPNP topline data expected Q2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.